Media - published on 01 Apr 2019

Access to medicines - business as usual?

The Lancet highlights key findings from the 2018 Access to Medicine Index, for example, that while all 20 pharmaceutical companies assessed have some form of access initiative in place, a small group of companies account for the most activity. The article also mentions company best practices featured in the Index, but goes on to question their actual impact on access.  

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.